Introduction
Pregnancy is a state of partial tolerance since, during a successful pregnancy, the maternal immune system is aware of, and actively tolerates, the semi-allogenic fetus without dramatically compromising the maternal defence against infections. CD4 (Foxp3), involved in Treg lineage commitment (3, 4) , is the best marker for Tregs. However, even though Foxp3 expression correlates with suppressive function in freshly isolated Tregs, Foxp3 can be up-regulated following in vitro activation of non-Tregs (5-7) and several factors such as hormones can influence Foxp3 expression (8) . Recently, the IL-7 receptor CD127 was shown to be negatively regulated by Foxp3, and low CD127 expression (CD127 low ), correlating with suppressive function, was suggested a surrogate surface marker for Foxp3 (9, 10) . Other molecules expressed by Tregs are HLA-DR and CTLA-4, both suggested to be involved in Treg suppression (11, 12) .
Tregs have been implicated in the successful maintenance of pregnancy in mice, where Tregs increase during normal pregnancy and their absence leads to gestational failure (13, 14) . In a murine abortion model, Tregs adoptively transferred from normal pregnant mice induce a fetal-protective microenvironment and provide protection against aggressive anti-fetal immune reactions (14, 15) . The cause of the Treg-protective mechanisms and Treg expansion seen during murine pregnancy has been ascribed pregnancy hormones (13) , foremost estrogens (16) , but also fetal alloantigens (14, 17) .
In line with these murine data, we have shown that during normal human pregnancy,
circulating Tregs suppress anti-fetal T H 1 and T H 2 like reactions as demonstrated by an in vitro
Treg mixed leukocyte culture (MLC) -ELISPOT assay (18) . However, the importance of Tregs in maintenance of human pregnancy in vivo is far from settled. Studies in humans have suggested that there is an increase in the CD4 + CD25 high population during normal pregnancy, most apparently at the fetal-maternal interface (19) (20) (21) but also in the circulation (19, (21) (22) (23) .
As in the murine system, estrogen seems to drive this suggested expansion (24) , whereas the role of other pregnancy hormones such as progesterone, is unknown. Further, it remains obscure if the previous observations reflect an increase of actual suppressive Tregs since more specific markers such as Foxp3 have not been thoroughly investigated previously. As pregnancy could be considered a state of controlled immune activation (25, 26) , possibly due to exposure and awareness of fetal antigens, the CD4 + CD25 high expansion seen during pregnancy might reflect an increase of activated CD4 + T cells. Thus, in such settings, Tregs should be better characterised by proteins such as Foxp3, CTLA-4, HLA-DR and the recently described marker CD127 low .
In this study, we aimed at determining the frequency, phenotype and function of stringently defined circulating Tregs in PBMC from healthy pregnant women, non-pregnant women and in vitro 17β-estradiol/progesterone stimulated PBMC of non-pregnant women. In contrast to most previous studies, only characterizing Tregs by CD4 and CD25 expression, we demonstrate a systemic reduction, caused mainly by progesterone but also by 17β-estradiol, of functionally suppressive CD4 dim CD25 high Foxp3 + Tregs in human second trimester pregnancy.
Subjects and Methods

Subjects
Thirty-eight healthy pregnant women with no signs of pregnancy complications at inclusion (pregnancy week [24] [25] [26] [27] [28] visiting the maternity outpatient care unit in Linköping (Kvinnohälsan), were asked to participate in the study. Obstetrical history of these women is given in table I. Twenty-five women were pregnant for the first time and thirteen had experienced at least one previous pregnancy. Five women had previously given birth at least once. Excluding women with previous pregnancy did not affect the statistical results.
Seventy-one non-pregnant women (age 19-36 years, median age 26), who were blood donors or staff at Linköping University Hospital, served as control subjects. There were no statistical age differences between pregnant and non-pregnant women. In the functional in vitro assays, none of the non-pregnant women (n=27) were using hormonal contraceptives. In the in vitro suppression assay, five of the women were in proliferative phase, six in secretory phase and three women were on day 15 in their menstrual cycle according to questionnaires. No such information was available from the other non-pregnant women. Informed consent was obtained from all participants. The study was approved by the Local Ethics Committee at Linköping University, Sweden.
PBMC preparation
Whole blood was obtained in EDTA (for flow cytometry) or sodium-heparin (for functional assays) vacutainer tubes. PBMC were separated within one hour on Lymphoprep (AxisShield, Oslo, Norway) according to the manufacturer's instructions followed by washing in (27) . One hundred thousand lymphocytes were collected and analyzed using FACSCalibur and the CellquestPro software (BD Biosciences). The Foxp3 antibody clone PCH101 binds the amino-terminus of the Foxp3 protein and has been shown to recognise both isoforms of the Foxp3 protein (7).
Six-color flow cytometry
PBMC from pregnant (n=10) and non-pregnant (n=10) women were analyzed by six-color flow cytometry to obtain a more detailed phenotype analysis. In addition, 17β-estradiol and progesterone stimulated PBMC (see below) were analyzed this way. Cells were labelled with isotype controls, as described above, or mouse anti-human CD3-APC-Cy7 (clone SK7), CD4-PerCP, CD25-APC, CD45RA-FITC (clone L48), CD45R0-PE-Cy7 (clone UCHL1), CD127-PE (clone hIL-7R-M21), CD69-PE-Cy7 (clone FN50) and HLA-DR-FITC (clone L243). This was followed by permeabilisation/fixation and staining of intracellular Foxp3 protein as described above. One hundred thousand lymphocytes were collected and analyzed using
FACSCanto II (BD Biosciences) and the FACSDiva software (version 5.0.1; BD Biosciences).
Absolute leukocyte (CD45), T lymphocyte (CD3) and T helper cell counts (CD4) in 50µL of EDTA whole blood were determined by using TruCount tubes (BD Biosciences) as described by the manufacturer.
Flow cytometric gating and analysis
All gating analysis was performed in a blinded manner, i.e. the evaluator did not know the origin of the sample. Cells were gated for analysis of lymphocytes by side/forward scatter, and in six-color flow cytometry, gating for analysis of T cells was also based on CD3
expression. Gates for expression of CD25 in the CD4 population (CD4
were set according to isotype controls. The CD25 high gate was adjusted to contain CD4 + cells that expressed higher levels of CD25 than the discrete population of CD4 -cells that expressed CD25 (28, 29) . This, and the development of other gating strategies, is further described in the results section. To avoid the possible errors introduced when subjectively setting any gate for CD25 high expression, the 0.5% of CD4 + cells expressing the highest levels of CD25 were also evaluated. These cells are referred to as "0.5% CD4 
Functional suppression assay -MACS-FACS-sorting and culturing conditions
The CD4 + T cell isolation kit II (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) was used for negative selection of untouched CD4 + cells from PBMC separated from pregnant (n=14) and non-pregnant women (n=14). CD4 + selection was performed according to the manufacturer's description using MS columns and a miniMACS separator (Miltenyi Biotec).
The 
Multiplex bead array analysis of IL-2, IL-4, IL-10, TNF-α and IFN-γ
Supernatants were analyzed by LINCOplex human cytokine kit according to the manufacturer's instructions using the Luminex 100 instrument (Luminex Corporation, Austin, Texas, USA). STarStation software (v 2.3, Applied Cytometry Systems, Sheffield, UK) was used for acquisition and analysis of data. The range of the standard curves was 0.13-10 000 pg/ml with a dilution factor of 5. The lowest (detection limit) and highest standard concentrations used for each cytokine was adjusted according to the standard curve fitting of the standard concentrations after mathematical interpolation. Values below the detection limit were given half the value of the detection limit. 
Statistics
The statistical guidance resource at Linköping University was consulted for the statistical analyzes. Due to multiple comparisons and the risk of mass significances, the significance level was set to 1%, i.e. p≤0.01 (sometimes depicted as **) was considered statistically significant and p≤0.05 (sometimes depicted as *) was regarded as a statistical tendency.
Results from the flow cytometric analyzes were analyzed using Student's unpaired t-test and presented as mean ± SD. Data on cytokines did not follow Gaussian distribution and were therefore analyzed using Wilcoxon signed rank test or Mann-Whitney U test and presented as medians and interquartile range (25 th and 75 th percentile values). Data on cytokines were also logarithmically transformed, to obtain Gaussian distribution, and analyzed using parametrical statistical methods. Since this did not affect the results, data was kept in linear mode and analyzed non-parametrically as described above. The coefficient of variation (CV) was expressed as percentage by calculating (SD/mean) x 100. All statistical analyzes were performed using the GraphPad Prism version 4 software (GraphPad Software Inc., San Diego, CA, USA). (Fig 2a-2b (fig 2c) . could be seen between pregnant and non-pregnant women and the expression of this marker was generally very low throughout the entire CD4 + population (around 1%; data not shown). fig 1a) , did not suppress the secretion of IL-2, TNF-α and IFN-γ (fig 7) . Rather, CD4 high CD25 high cells secreted high levels of IL-2, TNF-α and IFN-γ (fig 7) , as well as IL-4
Results
Determination
Figure 2. Expression of intracellular Foxp3 protein and mRNA in PBMC from pregnant and non-pregnant women. A. Expression of Foxp3 protein in CD4 + cells (pregnant n=14, nonpregnant n=32). B. Expression of Foxp3 protein in CD4 dim CD25 high (pregnant n=14, nonpregnant n=32). C. Expression of Foxp3 mRNA in total PBMC (pregnant n=13, nonpregnant n=25) D. Foxp3 fluorescence intensity (pregnant n=14, non-pregnant n=33) where peaks to the left in the figure are Foxp3
(median 1147 pg/mL; min 87 pg/mL, max 2413 pg/mL) and IL-10 (median 2294 pg/mL; min 15 pg/mL, max 2574 pg/mL), hence contributing to an increase in the bulk amount of these cytokines in co-culture with CD4 
Discussion
To evaluate the role for Tregs, in any condition, the defining of an accurate flow cytometric gate for analysis and sorting of these cells is a key prerequisite. In this study we thoroughly assessed the Treg gating strategy and thereby defined a distinct CD4 There are several suggestions as to the cause of the Treg modifications seen during pregnancy, the most prevailing being presence of fetal antigens and altered hormonal mileu. Our results draw attention to progesterone as a potent modulator of Tregs. We showed that progesterone, and to a lesser extent 17β-estradiol, were able to induce the here reported alterations in circulating Tregs in pregnancy, i.e. a reduction in frequency and an altered phenotype. We used hormone concentrations that are higher but comparable to those found physiologically at the fetal maternal interface during pregnancy (31, 32) . It should be noted that reliable information about local progesterone and 17β-estradiol concentrations is scarce. Importantly, hormone concentrations corresponding to serum levels (33, 34) caused slight but statistically not consistently significant changes that followed the very pronounced effects seen at higher concentrations. Expression of estrogen and progesterone receptors have been identified in various immune cells (35, 36) but to our knowledge, only receptors for estrogen have been confirmed on Tregs (24).
Our observations regarding 17β-estradiol are in contrast to the general consensus that in the murine system, Tregs are potentiated by 17β-estradiol (16, 37, 38) . Interestingly, under certain inflammatory conditions, human pregnancy levels of 17β-estradiol have been shown to enhance the expression of NF-κB (39), one of the targets for Foxp3 suppression (40) , in fact pointing towards a counteracting effect of 17β-estradiol on Tregs, in line with our results.
However, it was recently shown that 17β-estradiol increased the proliferation and function of human Tregs (24) . The discrepancies between the studies may be explained by differences in purity of the sorted Tregs, formulation of the 17β-estradiol used and also strength of the TCRstimulation in the in vitro assay. We used highly pure flow cytometry sorted Tregs, positive for Foxp3 expression, and water-soluble 17β-estradiol thereby avoiding the background cell activation caused by ethanol-soluble 17β-estradiol. Further, since pregnancy is a situation of alloantigen "awareness", our in vitro system with low grade of TCR stimulation seems more physiologically representative of pregnancy. Recently, Tregs and levels of 17β-estradiol, but not progesterone, were shown to correlate during the menstrual cycle (41) . However, as both 17β-estradiol and progesterone increase dramatically during pregnancy (33) and the effects of 17β-estradiol seem to be concentration-dependent (42) , the influence of these hormones might well be different during pregnancy. Our study suggests that even though both progesterone and 17β-estradiol have important and well documented immune modulating effects on pregnancy (43, 44) , these do not seem to be mediated via the promotion of Tregs.
We found an increased CD4 high CD25 high population in pregnant women (fig 1b) , probably being responsible for previous estimations of an increased circulating Treg population in pregnancy. Importantly, we showed that this population was non-suppressive and since it did not expand in response to neither progesterone nor 17β-estradiol, the expansion of this (19, (21) (22) (23) Tregs from pregnant women since Tregs, alone or in coculture, tended to secrete more IL-4
and IL-10 in pregnant as compared to non-pregnant women. Although these findings need further confirmation, this could be a mechanism by which maintained systemic tolerance is achieved, without the expansion of the Treg population.
In this study, we analyzed circulating Tregs, whereas the situation at the fetal-maternal interface may be different. The observed reduction in circulating Tregs could in fact be a consequence of a local recruitment to the decidua/placenta where Tregs seem enriched (20) and ought to have a more obvious role in protecting the fetus against detrimental immune reactions. During the writing of this manuscript, Tilburgs and colleagues reported that fetusspecific Treg cells could only be found at the fetal-maternal interface (45), whereas we previously found indications of fetus-specific Tregs in the circulation (18) . Thus, it is tempting to speculate that during pregnancy, non-fetus specific Tregs are down-regulated systemically to ensure optimal maternal defence against infections.
The pregnant women included in this study all displayed healthy pregnancies upon inclusion.
However, one woman delivered prematurely in gestational week 27. Data obtained from this woman did not diverge from the overall data pattern except for one point: In contrast to all the other pregnant women, Tregs from this woman did not secrete higher levels of IL-4 than did CD25 -T effector cells. We find this intriguing and with reservation to the fact that this is an isolated observation from a single patient, this may indicate a role for Treg-associated IL-4 production in healthy pregnancy. However, this finding has to be confirmed.
In conclusion, we show that circulating Tregs, defined as CD4 
